THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR…
Categorie
2024
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024 Positive efficacy and safety data of MaaT013…
May 7, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
May 6, 2024
MaaT Pharma to Hold Annual General Meeting on May 28, 2024 Lyon, France, April 22nd 2024 –7.30 am CET –…
April 22, 2024
MaaT Pharma Presents Positive 18-month Data for MaaT013 Showing a Clear Overall Survival Advantage in aGvHD from the Early Access…
April 15, 2024
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of…
April 9, 2024
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies Lyon, France, April…
April 8, 2024
MaaT Pharma Announces Initiation of Coverage of its Stock by Gilbert Dupont/ Groupe Société Générale Lyon, France, April 5 2024…
April 5, 2024
MaaT Pharma Announces 2023 Annual Results and Provides a Business Overview The DSMB, based on Phase 3 trial ARES preliminary…
March 28, 2024
MaaT Pharma Strengthens Executive Team Appointing Jonathan Chriqui as Chief Business Officer Lyon, France, March 21, 2024 –6.00pm CET –…
March 21, 2024
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.